Medical Care
Global Chronic Granulomatous Disease (CGD) Management Market Research Report 2025
- May 05, 25
- ID: 227102
- Pages: 88
- Figures: 84
- Views: 36
The global market for Chronic Granulomatous Disease (CGD) Management was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Chronic Granulomatous Disease (CGD) Management is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Chronic Granulomatous Disease (CGD) Management is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Chronic Granulomatous Disease (CGD) Management in Hospitals is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Chronic Granulomatous Disease (CGD) Management include Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Granulomatous Disease (CGD) Management, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Granulomatous Disease (CGD) Management.
The Chronic Granulomatous Disease (CGD) Management market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Granulomatous Disease (CGD) Management market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Granulomatous Disease (CGD) Management companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Clinigen Group plc
Orchard Therapeutics plc2032
Horizon Therapeutics plc
ViroMed. Co. Ltd
Bellicum Pharmaceuticals, Inc
Pfizer Inc
Hoffmann-La Roche Ltd
Novartis AG
Lonza
GlaxoSmithKline plc
Eli Lilly and Company
Johnson & Johnson Services, Inc
Merck KGaA
Segment by Type
X-Linked Chronic Granulomatous Disease
Autosomal Recessive Chronic Granulomatous Disease
Segment by Application
Hospitals
Specialty Clinics
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Granulomatous Disease (CGD) Management company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Chronic Granulomatous Disease (CGD) Management is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Chronic Granulomatous Disease (CGD) Management is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Chronic Granulomatous Disease (CGD) Management in Hospitals is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Chronic Granulomatous Disease (CGD) Management include Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Chronic Granulomatous Disease (CGD) Management, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Granulomatous Disease (CGD) Management.
The Chronic Granulomatous Disease (CGD) Management market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Granulomatous Disease (CGD) Management market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Granulomatous Disease (CGD) Management companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Clinigen Group plc
Orchard Therapeutics plc2032
Horizon Therapeutics plc
ViroMed. Co. Ltd
Bellicum Pharmaceuticals, Inc
Pfizer Inc
Hoffmann-La Roche Ltd
Novartis AG
Lonza
GlaxoSmithKline plc
Eli Lilly and Company
Johnson & Johnson Services, Inc
Merck KGaA
Segment by Type
X-Linked Chronic Granulomatous Disease
Autosomal Recessive Chronic Granulomatous Disease
Segment by Application
Hospitals
Specialty Clinics
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Granulomatous Disease (CGD) Management company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 X-Linked Chronic Granulomatous Disease
1.2.3 Autosomal Recessive Chronic Granulomatous Disease
1.3 Market by Application
1.3.1 Global Chronic Granulomatous Disease (CGD) Management Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Granulomatous Disease (CGD) Management Market Perspective (2020-2031)
2.2 Global Chronic Granulomatous Disease (CGD) Management Growth Trends by Region
2.2.1 Global Chronic Granulomatous Disease (CGD) Management Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Chronic Granulomatous Disease (CGD) Management Historic Market Size by Region (2020-2025)
2.2.3 Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Region (2026-2031)
2.3 Chronic Granulomatous Disease (CGD) Management Market Dynamics
2.3.1 Chronic Granulomatous Disease (CGD) Management Industry Trends
2.3.2 Chronic Granulomatous Disease (CGD) Management Market Drivers
2.3.3 Chronic Granulomatous Disease (CGD) Management Market Challenges
2.3.4 Chronic Granulomatous Disease (CGD) Management Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Granulomatous Disease (CGD) Management Players by Revenue
3.1.1 Global Top Chronic Granulomatous Disease (CGD) Management Players by Revenue (2020-2025)
3.1.2 Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Players (2020-2025)
3.2 Global Chronic Granulomatous Disease (CGD) Management Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chronic Granulomatous Disease (CGD) Management Revenue
3.4 Global Chronic Granulomatous Disease (CGD) Management Market Concentration Ratio
3.4.1 Global Chronic Granulomatous Disease (CGD) Management Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Granulomatous Disease (CGD) Management Revenue in 2024
3.5 Global Key Players of Chronic Granulomatous Disease (CGD) Management Head office and Area Served
3.6 Global Key Players of Chronic Granulomatous Disease (CGD) Management, Product and Application
3.7 Global Key Players of Chronic Granulomatous Disease (CGD) Management, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Granulomatous Disease (CGD) Management Breakdown Data by Type
4.1 Global Chronic Granulomatous Disease (CGD) Management Historic Market Size by Type (2020-2025)
4.2 Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Type (2026-2031)
5 Chronic Granulomatous Disease (CGD) Management Breakdown Data by Application
5.1 Global Chronic Granulomatous Disease (CGD) Management Historic Market Size by Application (2020-2025)
5.2 Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Chronic Granulomatous Disease (CGD) Management Market Size (2020-2031)
6.2 North America Chronic Granulomatous Disease (CGD) Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025)
6.4 North America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Granulomatous Disease (CGD) Management Market Size (2020-2031)
7.2 Europe Chronic Granulomatous Disease (CGD) Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025)
7.4 Europe Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size (2020-2031)
8.2 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size by Region (2020-2025)
8.4 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Granulomatous Disease (CGD) Management Market Size (2020-2031)
9.2 Latin America Chronic Granulomatous Disease (CGD) Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025)
9.4 Latin America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size (2020-2031)
10.2 Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025)
10.4 Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Clinigen Group plc
11.1.1 Clinigen Group plc Company Details
11.1.2 Clinigen Group plc Business Overview
11.1.3 Clinigen Group plc Chronic Granulomatous Disease (CGD) Management Introduction
11.1.4 Clinigen Group plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.1.5 Clinigen Group plc Recent Development
11.2 Orchard Therapeutics plc2032
11.2.1 Orchard Therapeutics plc2032 Company Details
11.2.2 Orchard Therapeutics plc2032 Business Overview
11.2.3 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Management Introduction
11.2.4 Orchard Therapeutics plc2032 Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.2.5 Orchard Therapeutics plc2032 Recent Development
11.3 Horizon Therapeutics plc
11.3.1 Horizon Therapeutics plc Company Details
11.3.2 Horizon Therapeutics plc Business Overview
11.3.3 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Management Introduction
11.3.4 Horizon Therapeutics plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.3.5 Horizon Therapeutics plc Recent Development
11.4 ViroMed. Co. Ltd
11.4.1 ViroMed. Co. Ltd Company Details
11.4.2 ViroMed. Co. Ltd Business Overview
11.4.3 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Management Introduction
11.4.4 ViroMed. Co. Ltd Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.4.5 ViroMed. Co. Ltd Recent Development
11.5 Bellicum Pharmaceuticals, Inc
11.5.1 Bellicum Pharmaceuticals, Inc Company Details
11.5.2 Bellicum Pharmaceuticals, Inc Business Overview
11.5.3 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Management Introduction
11.5.4 Bellicum Pharmaceuticals, Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.5.5 Bellicum Pharmaceuticals, Inc Recent Development
11.6 Pfizer Inc
11.6.1 Pfizer Inc Company Details
11.6.2 Pfizer Inc Business Overview
11.6.3 Pfizer Inc Chronic Granulomatous Disease (CGD) Management Introduction
11.6.4 Pfizer Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.6.5 Pfizer Inc Recent Development
11.7 Hoffmann-La Roche Ltd
11.7.1 Hoffmann-La Roche Ltd Company Details
11.7.2 Hoffmann-La Roche Ltd Business Overview
11.7.3 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Management Introduction
11.7.4 Hoffmann-La Roche Ltd Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.7.5 Hoffmann-La Roche Ltd Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Details
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Chronic Granulomatous Disease (CGD) Management Introduction
11.8.4 Novartis AG Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.8.5 Novartis AG Recent Development
11.9 Lonza
11.9.1 Lonza Company Details
11.9.2 Lonza Business Overview
11.9.3 Lonza Chronic Granulomatous Disease (CGD) Management Introduction
11.9.4 Lonza Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.9.5 Lonza Recent Development
11.10 GlaxoSmithKline plc
11.10.1 GlaxoSmithKline plc Company Details
11.10.2 GlaxoSmithKline plc Business Overview
11.10.3 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Management Introduction
11.10.4 GlaxoSmithKline plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.10.5 GlaxoSmithKline plc Recent Development
11.11 Eli Lilly and Company
11.11.1 Eli Lilly and Company Company Details
11.11.2 Eli Lilly and Company Business Overview
11.11.3 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Management Introduction
11.11.4 Eli Lilly and Company Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.11.5 Eli Lilly and Company Recent Development
11.12 Johnson & Johnson Services, Inc
11.12.1 Johnson & Johnson Services, Inc Company Details
11.12.2 Johnson & Johnson Services, Inc Business Overview
11.12.3 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Management Introduction
11.12.4 Johnson & Johnson Services, Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.12.5 Johnson & Johnson Services, Inc Recent Development
11.13 Merck KGaA
11.13.1 Merck KGaA Company Details
11.13.2 Merck KGaA Business Overview
11.13.3 Merck KGaA Chronic Granulomatous Disease (CGD) Management Introduction
11.13.4 Merck KGaA Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.13.5 Merck KGaA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 X-Linked Chronic Granulomatous Disease
1.2.3 Autosomal Recessive Chronic Granulomatous Disease
1.3 Market by Application
1.3.1 Global Chronic Granulomatous Disease (CGD) Management Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Granulomatous Disease (CGD) Management Market Perspective (2020-2031)
2.2 Global Chronic Granulomatous Disease (CGD) Management Growth Trends by Region
2.2.1 Global Chronic Granulomatous Disease (CGD) Management Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Chronic Granulomatous Disease (CGD) Management Historic Market Size by Region (2020-2025)
2.2.3 Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Region (2026-2031)
2.3 Chronic Granulomatous Disease (CGD) Management Market Dynamics
2.3.1 Chronic Granulomatous Disease (CGD) Management Industry Trends
2.3.2 Chronic Granulomatous Disease (CGD) Management Market Drivers
2.3.3 Chronic Granulomatous Disease (CGD) Management Market Challenges
2.3.4 Chronic Granulomatous Disease (CGD) Management Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Granulomatous Disease (CGD) Management Players by Revenue
3.1.1 Global Top Chronic Granulomatous Disease (CGD) Management Players by Revenue (2020-2025)
3.1.2 Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Players (2020-2025)
3.2 Global Chronic Granulomatous Disease (CGD) Management Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chronic Granulomatous Disease (CGD) Management Revenue
3.4 Global Chronic Granulomatous Disease (CGD) Management Market Concentration Ratio
3.4.1 Global Chronic Granulomatous Disease (CGD) Management Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Granulomatous Disease (CGD) Management Revenue in 2024
3.5 Global Key Players of Chronic Granulomatous Disease (CGD) Management Head office and Area Served
3.6 Global Key Players of Chronic Granulomatous Disease (CGD) Management, Product and Application
3.7 Global Key Players of Chronic Granulomatous Disease (CGD) Management, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Granulomatous Disease (CGD) Management Breakdown Data by Type
4.1 Global Chronic Granulomatous Disease (CGD) Management Historic Market Size by Type (2020-2025)
4.2 Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Type (2026-2031)
5 Chronic Granulomatous Disease (CGD) Management Breakdown Data by Application
5.1 Global Chronic Granulomatous Disease (CGD) Management Historic Market Size by Application (2020-2025)
5.2 Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Chronic Granulomatous Disease (CGD) Management Market Size (2020-2031)
6.2 North America Chronic Granulomatous Disease (CGD) Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025)
6.4 North America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Granulomatous Disease (CGD) Management Market Size (2020-2031)
7.2 Europe Chronic Granulomatous Disease (CGD) Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025)
7.4 Europe Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size (2020-2031)
8.2 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size by Region (2020-2025)
8.4 Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Granulomatous Disease (CGD) Management Market Size (2020-2031)
9.2 Latin America Chronic Granulomatous Disease (CGD) Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025)
9.4 Latin America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size (2020-2031)
10.2 Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025)
10.4 Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Clinigen Group plc
11.1.1 Clinigen Group plc Company Details
11.1.2 Clinigen Group plc Business Overview
11.1.3 Clinigen Group plc Chronic Granulomatous Disease (CGD) Management Introduction
11.1.4 Clinigen Group plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.1.5 Clinigen Group plc Recent Development
11.2 Orchard Therapeutics plc2032
11.2.1 Orchard Therapeutics plc2032 Company Details
11.2.2 Orchard Therapeutics plc2032 Business Overview
11.2.3 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Management Introduction
11.2.4 Orchard Therapeutics plc2032 Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.2.5 Orchard Therapeutics plc2032 Recent Development
11.3 Horizon Therapeutics plc
11.3.1 Horizon Therapeutics plc Company Details
11.3.2 Horizon Therapeutics plc Business Overview
11.3.3 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Management Introduction
11.3.4 Horizon Therapeutics plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.3.5 Horizon Therapeutics plc Recent Development
11.4 ViroMed. Co. Ltd
11.4.1 ViroMed. Co. Ltd Company Details
11.4.2 ViroMed. Co. Ltd Business Overview
11.4.3 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Management Introduction
11.4.4 ViroMed. Co. Ltd Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.4.5 ViroMed. Co. Ltd Recent Development
11.5 Bellicum Pharmaceuticals, Inc
11.5.1 Bellicum Pharmaceuticals, Inc Company Details
11.5.2 Bellicum Pharmaceuticals, Inc Business Overview
11.5.3 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Management Introduction
11.5.4 Bellicum Pharmaceuticals, Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.5.5 Bellicum Pharmaceuticals, Inc Recent Development
11.6 Pfizer Inc
11.6.1 Pfizer Inc Company Details
11.6.2 Pfizer Inc Business Overview
11.6.3 Pfizer Inc Chronic Granulomatous Disease (CGD) Management Introduction
11.6.4 Pfizer Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.6.5 Pfizer Inc Recent Development
11.7 Hoffmann-La Roche Ltd
11.7.1 Hoffmann-La Roche Ltd Company Details
11.7.2 Hoffmann-La Roche Ltd Business Overview
11.7.3 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Management Introduction
11.7.4 Hoffmann-La Roche Ltd Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.7.5 Hoffmann-La Roche Ltd Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Details
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Chronic Granulomatous Disease (CGD) Management Introduction
11.8.4 Novartis AG Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.8.5 Novartis AG Recent Development
11.9 Lonza
11.9.1 Lonza Company Details
11.9.2 Lonza Business Overview
11.9.3 Lonza Chronic Granulomatous Disease (CGD) Management Introduction
11.9.4 Lonza Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.9.5 Lonza Recent Development
11.10 GlaxoSmithKline plc
11.10.1 GlaxoSmithKline plc Company Details
11.10.2 GlaxoSmithKline plc Business Overview
11.10.3 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Management Introduction
11.10.4 GlaxoSmithKline plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.10.5 GlaxoSmithKline plc Recent Development
11.11 Eli Lilly and Company
11.11.1 Eli Lilly and Company Company Details
11.11.2 Eli Lilly and Company Business Overview
11.11.3 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Management Introduction
11.11.4 Eli Lilly and Company Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.11.5 Eli Lilly and Company Recent Development
11.12 Johnson & Johnson Services, Inc
11.12.1 Johnson & Johnson Services, Inc Company Details
11.12.2 Johnson & Johnson Services, Inc Business Overview
11.12.3 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Management Introduction
11.12.4 Johnson & Johnson Services, Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.12.5 Johnson & Johnson Services, Inc Recent Development
11.13 Merck KGaA
11.13.1 Merck KGaA Company Details
11.13.2 Merck KGaA Business Overview
11.13.3 Merck KGaA Chronic Granulomatous Disease (CGD) Management Introduction
11.13.4 Merck KGaA Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
11.13.5 Merck KGaA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of X-Linked Chronic Granulomatous Disease
Table 3. Key Players of Autosomal Recessive Chronic Granulomatous Disease
Table 4. Global Chronic Granulomatous Disease (CGD) Management Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Chronic Granulomatous Disease (CGD) Management Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Chronic Granulomatous Disease (CGD) Management Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Chronic Granulomatous Disease (CGD) Management Market Share by Region (2020-2025)
Table 8. Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Chronic Granulomatous Disease (CGD) Management Market Share by Region (2026-2031)
Table 10. Chronic Granulomatous Disease (CGD) Management Market Trends
Table 11. Chronic Granulomatous Disease (CGD) Management Market Drivers
Table 12. Chronic Granulomatous Disease (CGD) Management Market Challenges
Table 13. Chronic Granulomatous Disease (CGD) Management Market Restraints
Table 14. Global Chronic Granulomatous Disease (CGD) Management Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Chronic Granulomatous Disease (CGD) Management Market Share by Players (2020-2025)
Table 16. Global Top Chronic Granulomatous Disease (CGD) Management Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Management as of 2024)
Table 17. Ranking of Global Top Chronic Granulomatous Disease (CGD) Management Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Chronic Granulomatous Disease (CGD) Management Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Chronic Granulomatous Disease (CGD) Management, Headquarters and Area Served
Table 20. Global Key Players of Chronic Granulomatous Disease (CGD) Management, Product and Application
Table 21. Global Key Players of Chronic Granulomatous Disease (CGD) Management, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Chronic Granulomatous Disease (CGD) Management Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Type (2020-2025)
Table 25. Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Type (2026-2031)
Table 27. Global Chronic Granulomatous Disease (CGD) Management Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Application (2020-2025)
Table 29. Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Application (2026-2031)
Table 31. North America Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031) & (US$ Million)
Table 46. Clinigen Group plc Company Details
Table 47. Clinigen Group plc Business Overview
Table 48. Clinigen Group plc Chronic Granulomatous Disease (CGD) Management Product
Table 49. Clinigen Group plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 50. Clinigen Group plc Recent Development
Table 51. Orchard Therapeutics plc2032 Company Details
Table 52. Orchard Therapeutics plc2032 Business Overview
Table 53. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Management Product
Table 54. Orchard Therapeutics plc2032 Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 55. Orchard Therapeutics plc2032 Recent Development
Table 56. Horizon Therapeutics plc Company Details
Table 57. Horizon Therapeutics plc Business Overview
Table 58. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Management Product
Table 59. Horizon Therapeutics plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 60. Horizon Therapeutics plc Recent Development
Table 61. ViroMed. Co. Ltd Company Details
Table 62. ViroMed. Co. Ltd Business Overview
Table 63. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Management Product
Table 64. ViroMed. Co. Ltd Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 65. ViroMed. Co. Ltd Recent Development
Table 66. Bellicum Pharmaceuticals, Inc Company Details
Table 67. Bellicum Pharmaceuticals, Inc Business Overview
Table 68. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Management Product
Table 69. Bellicum Pharmaceuticals, Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 70. Bellicum Pharmaceuticals, Inc Recent Development
Table 71. Pfizer Inc Company Details
Table 72. Pfizer Inc Business Overview
Table 73. Pfizer Inc Chronic Granulomatous Disease (CGD) Management Product
Table 74. Pfizer Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 75. Pfizer Inc Recent Development
Table 76. Hoffmann-La Roche Ltd Company Details
Table 77. Hoffmann-La Roche Ltd Business Overview
Table 78. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Management Product
Table 79. Hoffmann-La Roche Ltd Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 80. Hoffmann-La Roche Ltd Recent Development
Table 81. Novartis AG Company Details
Table 82. Novartis AG Business Overview
Table 83. Novartis AG Chronic Granulomatous Disease (CGD) Management Product
Table 84. Novartis AG Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 85. Novartis AG Recent Development
Table 86. Lonza Company Details
Table 87. Lonza Business Overview
Table 88. Lonza Chronic Granulomatous Disease (CGD) Management Product
Table 89. Lonza Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 90. Lonza Recent Development
Table 91. GlaxoSmithKline plc Company Details
Table 92. GlaxoSmithKline plc Business Overview
Table 93. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Management Product
Table 94. GlaxoSmithKline plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 95. GlaxoSmithKline plc Recent Development
Table 96. Eli Lilly and Company Company Details
Table 97. Eli Lilly and Company Business Overview
Table 98. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Management Product
Table 99. Eli Lilly and Company Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 100. Eli Lilly and Company Recent Development
Table 101. Johnson & Johnson Services, Inc Company Details
Table 102. Johnson & Johnson Services, Inc Business Overview
Table 103. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Management Product
Table 104. Johnson & Johnson Services, Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 105. Johnson & Johnson Services, Inc Recent Development
Table 106. Merck KGaA Company Details
Table 107. Merck KGaA Business Overview
Table 108. Merck KGaA Chronic Granulomatous Disease (CGD) Management Product
Table 109. Merck KGaA Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 110. Merck KGaA Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
Table 114. Authors List of This Report
List of Figures
Figure 1. Chronic Granulomatous Disease (CGD) Management Picture
Figure 2. Global Chronic Granulomatous Disease (CGD) Management Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Chronic Granulomatous Disease (CGD) Management Market Share by Type: 2024 VS 2031
Figure 4. X-Linked Chronic Granulomatous Disease Features
Figure 5. Autosomal Recessive Chronic Granulomatous Disease Features
Figure 6. Global Chronic Granulomatous Disease (CGD) Management Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Chronic Granulomatous Disease (CGD) Management Market Share by Application: 2024 VS 2031
Figure 8. Hospitals Case Studies
Figure 9. Specialty Clinics Case Studies
Figure 10. Chronic Granulomatous Disease (CGD) Management Report Years Considered
Figure 11. Global Chronic Granulomatous Disease (CGD) Management Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Chronic Granulomatous Disease (CGD) Management Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Chronic Granulomatous Disease (CGD) Management Market Share by Region: 2024 VS 2031
Figure 14. Global Chronic Granulomatous Disease (CGD) Management Market Share by Players in 2024
Figure 15. Global Top Chronic Granulomatous Disease (CGD) Management Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Management as of 2024)
Figure 16. The Top 10 and 5 Players Market Share by Chronic Granulomatous Disease (CGD) Management Revenue in 2024
Figure 17. North America Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 18. North America Chronic Granulomatous Disease (CGD) Management Market Share by Country (2020-2031)
Figure 19. United States Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. Canada Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Europe Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Chronic Granulomatous Disease (CGD) Management Market Share by Country (2020-2031)
Figure 23. Germany Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. France Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. U.K. Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Italy Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Russia Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Nordic Countries Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Share by Region (2020-2031)
Figure 31. China Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Japan Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. South Korea Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Southeast Asia Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. India Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Australia Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Latin America Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Chronic Granulomatous Disease (CGD) Management Market Share by Country (2020-2031)
Figure 39. Mexico Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Brazil Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Share by Country (2020-2031)
Figure 43. Turkey Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Saudi Arabia Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. UAE Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Clinigen Group plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 47. Orchard Therapeutics plc2032 Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 48. Horizon Therapeutics plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 49. ViroMed. Co. Ltd Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 50. Bellicum Pharmaceuticals, Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 51. Pfizer Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 52. Hoffmann-La Roche Ltd Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 53. Novartis AG Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 54. Lonza Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 55. GlaxoSmithKline plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 56. Eli Lilly and Company Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 57. Johnson & Johnson Services, Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 58. Merck KGaA Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Table 1. Global Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of X-Linked Chronic Granulomatous Disease
Table 3. Key Players of Autosomal Recessive Chronic Granulomatous Disease
Table 4. Global Chronic Granulomatous Disease (CGD) Management Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Chronic Granulomatous Disease (CGD) Management Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Chronic Granulomatous Disease (CGD) Management Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Chronic Granulomatous Disease (CGD) Management Market Share by Region (2020-2025)
Table 8. Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Chronic Granulomatous Disease (CGD) Management Market Share by Region (2026-2031)
Table 10. Chronic Granulomatous Disease (CGD) Management Market Trends
Table 11. Chronic Granulomatous Disease (CGD) Management Market Drivers
Table 12. Chronic Granulomatous Disease (CGD) Management Market Challenges
Table 13. Chronic Granulomatous Disease (CGD) Management Market Restraints
Table 14. Global Chronic Granulomatous Disease (CGD) Management Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Chronic Granulomatous Disease (CGD) Management Market Share by Players (2020-2025)
Table 16. Global Top Chronic Granulomatous Disease (CGD) Management Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Management as of 2024)
Table 17. Ranking of Global Top Chronic Granulomatous Disease (CGD) Management Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Chronic Granulomatous Disease (CGD) Management Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Chronic Granulomatous Disease (CGD) Management, Headquarters and Area Served
Table 20. Global Key Players of Chronic Granulomatous Disease (CGD) Management, Product and Application
Table 21. Global Key Players of Chronic Granulomatous Disease (CGD) Management, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Chronic Granulomatous Disease (CGD) Management Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Type (2020-2025)
Table 25. Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Type (2026-2031)
Table 27. Global Chronic Granulomatous Disease (CGD) Management Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Application (2020-2025)
Table 29. Global Chronic Granulomatous Disease (CGD) Management Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Chronic Granulomatous Disease (CGD) Management Revenue Market Share by Application (2026-2031)
Table 31. North America Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size by Country (2026-2031) & (US$ Million)
Table 46. Clinigen Group plc Company Details
Table 47. Clinigen Group plc Business Overview
Table 48. Clinigen Group plc Chronic Granulomatous Disease (CGD) Management Product
Table 49. Clinigen Group plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 50. Clinigen Group plc Recent Development
Table 51. Orchard Therapeutics plc2032 Company Details
Table 52. Orchard Therapeutics plc2032 Business Overview
Table 53. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Management Product
Table 54. Orchard Therapeutics plc2032 Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 55. Orchard Therapeutics plc2032 Recent Development
Table 56. Horizon Therapeutics plc Company Details
Table 57. Horizon Therapeutics plc Business Overview
Table 58. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Management Product
Table 59. Horizon Therapeutics plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 60. Horizon Therapeutics plc Recent Development
Table 61. ViroMed. Co. Ltd Company Details
Table 62. ViroMed. Co. Ltd Business Overview
Table 63. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Management Product
Table 64. ViroMed. Co. Ltd Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 65. ViroMed. Co. Ltd Recent Development
Table 66. Bellicum Pharmaceuticals, Inc Company Details
Table 67. Bellicum Pharmaceuticals, Inc Business Overview
Table 68. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Management Product
Table 69. Bellicum Pharmaceuticals, Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 70. Bellicum Pharmaceuticals, Inc Recent Development
Table 71. Pfizer Inc Company Details
Table 72. Pfizer Inc Business Overview
Table 73. Pfizer Inc Chronic Granulomatous Disease (CGD) Management Product
Table 74. Pfizer Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 75. Pfizer Inc Recent Development
Table 76. Hoffmann-La Roche Ltd Company Details
Table 77. Hoffmann-La Roche Ltd Business Overview
Table 78. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Management Product
Table 79. Hoffmann-La Roche Ltd Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 80. Hoffmann-La Roche Ltd Recent Development
Table 81. Novartis AG Company Details
Table 82. Novartis AG Business Overview
Table 83. Novartis AG Chronic Granulomatous Disease (CGD) Management Product
Table 84. Novartis AG Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 85. Novartis AG Recent Development
Table 86. Lonza Company Details
Table 87. Lonza Business Overview
Table 88. Lonza Chronic Granulomatous Disease (CGD) Management Product
Table 89. Lonza Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 90. Lonza Recent Development
Table 91. GlaxoSmithKline plc Company Details
Table 92. GlaxoSmithKline plc Business Overview
Table 93. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Management Product
Table 94. GlaxoSmithKline plc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 95. GlaxoSmithKline plc Recent Development
Table 96. Eli Lilly and Company Company Details
Table 97. Eli Lilly and Company Business Overview
Table 98. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Management Product
Table 99. Eli Lilly and Company Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 100. Eli Lilly and Company Recent Development
Table 101. Johnson & Johnson Services, Inc Company Details
Table 102. Johnson & Johnson Services, Inc Business Overview
Table 103. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Management Product
Table 104. Johnson & Johnson Services, Inc Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 105. Johnson & Johnson Services, Inc Recent Development
Table 106. Merck KGaA Company Details
Table 107. Merck KGaA Business Overview
Table 108. Merck KGaA Chronic Granulomatous Disease (CGD) Management Product
Table 109. Merck KGaA Revenue in Chronic Granulomatous Disease (CGD) Management Business (2020-2025) & (US$ Million)
Table 110. Merck KGaA Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
Table 114. Authors List of This Report
List of Figures
Figure 1. Chronic Granulomatous Disease (CGD) Management Picture
Figure 2. Global Chronic Granulomatous Disease (CGD) Management Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Chronic Granulomatous Disease (CGD) Management Market Share by Type: 2024 VS 2031
Figure 4. X-Linked Chronic Granulomatous Disease Features
Figure 5. Autosomal Recessive Chronic Granulomatous Disease Features
Figure 6. Global Chronic Granulomatous Disease (CGD) Management Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Chronic Granulomatous Disease (CGD) Management Market Share by Application: 2024 VS 2031
Figure 8. Hospitals Case Studies
Figure 9. Specialty Clinics Case Studies
Figure 10. Chronic Granulomatous Disease (CGD) Management Report Years Considered
Figure 11. Global Chronic Granulomatous Disease (CGD) Management Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Chronic Granulomatous Disease (CGD) Management Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Chronic Granulomatous Disease (CGD) Management Market Share by Region: 2024 VS 2031
Figure 14. Global Chronic Granulomatous Disease (CGD) Management Market Share by Players in 2024
Figure 15. Global Top Chronic Granulomatous Disease (CGD) Management Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Management as of 2024)
Figure 16. The Top 10 and 5 Players Market Share by Chronic Granulomatous Disease (CGD) Management Revenue in 2024
Figure 17. North America Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 18. North America Chronic Granulomatous Disease (CGD) Management Market Share by Country (2020-2031)
Figure 19. United States Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. Canada Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Europe Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Chronic Granulomatous Disease (CGD) Management Market Share by Country (2020-2031)
Figure 23. Germany Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. France Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. U.K. Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Italy Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Russia Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Nordic Countries Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Chronic Granulomatous Disease (CGD) Management Market Share by Region (2020-2031)
Figure 31. China Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Japan Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. South Korea Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Southeast Asia Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. India Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Australia Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Latin America Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Chronic Granulomatous Disease (CGD) Management Market Share by Country (2020-2031)
Figure 39. Mexico Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Brazil Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Chronic Granulomatous Disease (CGD) Management Market Share by Country (2020-2031)
Figure 43. Turkey Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Saudi Arabia Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. UAE Chronic Granulomatous Disease (CGD) Management Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Clinigen Group plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 47. Orchard Therapeutics plc2032 Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 48. Horizon Therapeutics plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 49. ViroMed. Co. Ltd Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 50. Bellicum Pharmaceuticals, Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 51. Pfizer Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 52. Hoffmann-La Roche Ltd Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 53. Novartis AG Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 54. Lonza Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 55. GlaxoSmithKline plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 56. Eli Lilly and Company Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 57. Johnson & Johnson Services, Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 58. Merck KGaA Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Management Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Potassium Bromide Windows Market Research Report 2025
Dec 14, 25
Global Bio-based 1,10-Decanediol Diacrylate Market Research Report 2025
Dec 14, 25
Global Bio-based 1,5-Pentanediol Diacrylate(PDDA) Market Research Report 2025
Dec 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232